Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
|Articles|December 1, 2001
Rx marketing 'e-events' increasing
The Internet has become a new meeting place for drug companies and doctors, according to the Physician Meeting and Event Audit from Newtown, PA-based Scott-Levin. From February through April 2001, Scott-Levin surveyed its PMEA panel every month to determine the extent of "e-event" activity. More than 3,100 physicians participated in the study; 39% indicated that they had been invited to at least one pharmaceutical company-sponsored event conducted via the Internet.
Advertisement
The Internet has become a new meeting place for drug companies and doctors, according to the Physician Meeting and Event Audit from Newtown, PA-based Scott-Levin. From February through April 2001, Scott-Levin surveyed its PMEA panel every month to determine the extent of "e-event" activity. More than 3,100 physicians participated in the study; 39% indicated that they had been invited to at least one pharmaceutical company-sponsored event conducted via the Internet.
Specialists with the highest percentages of e-event invitations were allergists/immunologists (58% invited), psychiatrists (53%) and gastroenterologists (51%).
In addition, 30% of doctors said their attitude toward e-events was positive, and 64% said they planned to participate in future events.
Research Triangle Park, NC-based GlaxoSmithKline led in e-events offered during the spring, accounting for more than 14% of activity, followed by Whitehouse Station, NJ-based Merck & Co. Inc., with almost 13% of e-events. PR
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
Understanding the Latest with MFN Pricing and What It Means to Pharma
4
Novo Announces Drug Discovery Collaboration with Anthropic
5